转移性割抗性前列腺癌患者的系统治疗:ASCO指南更新
Rohan Garje1, Irbaz Bin Riaz2, Syed Arsalan Ahmed Naqvi2
1Miami Cancer Institute, Baptist Health South Florida, Miami, FL.
概括
基于证据的指导方针建议基于先前的治疗方法对转移性割抵抗性前列腺癌 (mCRPC) 进行特定的治疗. 关键建议包括雄激素受体通路抑制剂 (ARPIs),多ADP-核糖) 聚合酶抑制剂 (PARPi) 和放射性药物,以改善生存.
科学领域:
- 在瘤学瘤学.
- 生殖尿道癌症 生殖尿道癌症
- 前列腺癌治疗方法 前列腺癌治疗方法
背景情况:
- 转移性割抵抗性前列腺癌 (mCRPC) 提出了复杂的治疗挑战.
- 以前的治疗史显著影响后续疗法的疗效.
- 随着治疗选择的不断发展,需要更新基于证据的建议.
研究的目的:
- 为患有mCRPC的患者制定基于证据的治疗建议.
- 为瘤学家和患者护理团队指导临床决策.
- 为了结合mCRPC治疗的最新进展.
主要方法:
- 对现有证据进行系统审查.
- 专家小组审查,包括患者代表.
- 基于综合数据的临床建议的制定.
主要成果:
- 雄激素受体通路抑制剂 (ARPI),PARP抑制剂 (PARPi),化疗 (docetaxel,cabazitaxel) 和放射性药物 (223,177Lu-PSMA-617) 在mCRPC中显示出整体生存 (OS) 的好处.
- ARPI和PARPi的组合在BRCA改变的mCRPC中显示出好处.
- 根据基因变异和先前的治疗方法,针对不同患者亚组推使用Olaparib,Pembrolizumab和Radium 223等特定药物.
结论:
- 对mCRPC的治疗顺序取决于先前对割敏感疾病的全身治疗.
- 抗雄激素缺乏治疗应继续无限期;建议早期进行基因检测和息治疗.
- 具体建议包括ARPI + PARPi用于ARPI-naive BRCA-altered mCRPC,先前ARPI后的多塞,以及先前ARPI和多塞后的177Lu-PSMA-617或cabazitaxel.
更多相关视频
12:13Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
Published on: November 19, 2019
6.7K
06:44Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
Published on: September 8, 2017
13.2K
相关概念视频
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
02:49Cancer Therapies
7.4K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.4K